Navigation Links
U.S. Commerce Secretary Gutierrez Cuts Ribbon on MaxWell Biocorporation's New Pharmaceutical Development Center and Quality Control Laboratory in Ukraine
Date:6/24/2008

- First U.S. Commerce Secretary to visit independent Ukraine also visits

MaxWell's newly-built Boryspil facility -

WASHINGTON, June 24 /PRNewswire/ -- On June 4, 2008, U.S. Commerce Secretary Carlos Gutierrez became the first U.S. cabinet official to visit MaxWell Biocorporation's 150,000-square-foot pharmaceutical production facility in Boryspil, Ukraine.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080624/NETU078LOGO )

Gutierrez joined the founder, President and CEO of MaxWell Biocorporation Dr. Ken Alibek to officially open MaxWell's new pharmaceutical development center and quality control laboratory, co-located with the larger pharmaceutical production facility that opened officially on March 26, 2008.

Gutierrez and Alibek were joined at the ribbon-cutting ceremony by U.S. Ambassador to Ukraine William Taylor, President of the Academy of Medical Sciences of Ukraine Olexander F. Vozianov, and representatives of leading pharmaceutical companies in Ukraine.

Gutierrez visited MaxWell Biocorporation's Boryspil facility during his official trip to Ukraine on June 4-5. The U.S. Commerce Secretary also addressed the American Chamber of Commerce in Kyiv, held a roundtable discussion with U.S. business leaders, and met with Ukraine's President Yushchenko, Prime Minister Tymoshenko, and other senior Ukrainian officials to promote greater bilateral trade and investment.

According to the U.S. Department of Commerce, bilateral trade between the United States and Ukraine exceeded $2.5 billion in 2007, with U.S. exports growing by more than 77 percent. Ukraine's pharmaceutical market alone grew an estimated 22% in 2007, with 12% growth predicted for 2008.

Earlier this year, the United States and Ukraine concluded a Trade and Investment Cooperation Agreement, which establishes a framework for a deeper dialogue on trade and investment.

Photos of the event may be accessed on the MaxWell corporate website (http://www.max-well.com/eng/company_news.php?news_id=250) and on the U.S. Commerce Department home page ( http://www.commerce.gov/NewsRoom/TopNews/Images/PROD01_006605 ).

About MaxWell

MaxWell Biocorporation is a U.S.-based, privately-held international medical and pharmaceutical company with wholly owned subsidiaries and affiliates in the United States and Ukraine dedicated to increasing life expectancy and improving the quality of life of people in Ukraine and other underserved emerging healthcare markets in the former Soviet Union. MaxWell targets oncological, cardiological, chronic infectious and autoimmune disorders and diseases through the development, production, and introduction into clinical practice of sophisticated, high quality, and affordable off-patent generic biopharmaceutical and chemopharmaceutical medicines and the latest diagnostic and therapeutic methods. MaxWell = "Maximum Wellness."

"We Help You Live Longer"

Contact:

Alex Meerovich

A.Meerovich@max-well.com

202-454-3403


'/>"/>
SOURCE MaxWell Biocorporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. U.S. Commerce Secretary Gutierrez to Address AdvaMed 2007
2. Sigma-Aldrich and Ingenuity Systems Announce Partnership to Create E-Commerce Search Solution Based on Biological Knowledge
3. HHS Secretary Leavitt Announces Members of the National Biodefense Science Board
4. Carbon nanoribbons could make smaller, speedier computer chips
5. CTDC Holds a Ribbon Cutting Ceremony to Showcase First SnO2 Production Line
6. Sun Pharmaceutical Sends Second Letter to Taro Pharmaceutical Regarding Taros Irish Subsidiary
7. Keryx Biopharmaceuticals to Present at the Jefferies & Co. Healthcare Conference
8. Portola Pharmaceuticals Names William Lis Vice President of Business Development and Commercial Operations
9. Stason Pharmaceuticals, Inc. Appoints Diana Wood as Vice President, Business Development
10. In Pain Market, Huge Unmet Needs, Tough Regulatory Environment Challenge Pharmaceutical Companies, According to MedPredict
11. Brian Levy, OD, MSc, Named Chief Operating Officer of Danube Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... -- Summary This report provides all the ... partnering interests and activities since 2010. Description The Partnering ... into the partnering activity of one of the world,s leading ... prepared upon purchase to ensure inclusion of the most up ... will be delivered in PDF format within 1 working day ...
(Date:3/28/2017)... March 28, 2017  Viking Therapeutics, Inc. ("Viking") (NASDAQ: ... of novel therapies for metabolic and endocrine disorders, today ... , Ph.D., will deliver a corporate presentation at H.C. ... Conference, being held April 3, 2017 at the St. ... for this presentation are as follows: ...
(Date:3/28/2017)... ... March 28, 2017 , ... Currently symptomatic therapies for ... recent study published in STEM CELLS suggests that human neural stem cell (hNSC) ... to produce more neural cells. , Strategies involving transplantation of these cells ...
(Date:3/28/2017)... Triangle Park, NC (PRWEB) , ... March 28, ... ... development company engaged in the development of a new orally administered treatment for ... Advisory Board. , CEO John Didsbury states, “As we seek to uniquely treat ...
Breaking Biology Technology:
(Date:2/16/2017)... 2017  Genos, a community for personal genetic ... received Laboratory Accreditation from the College of American ... laboratories that meet stringent requirements around quality, accuracy ... "Genos is committed to maintaining the ... honored to be receiving CAP accreditation," said ...
(Date:2/13/2017)... SAN FRANCISCO , Feb. 13, 2017 /PRNewswire/ ... a centralized platform that is designed to enhance ... the latest release in the RSA Fraud & ... to enable organizations to leverage additional insights from ... anti-fraud tools to better protect their customers from ...
(Date:2/10/2017)... Research and Markets has announced the addition of ... Commercial Aspects" to their offering. ... Biomarkers play an important ... selection of treatment as well for monitoring the results. There ... modern medicine. Biochip/microarray technologies and next generation sequencing are also ...
Breaking Biology News(10 mins):